GSK

The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

It's Electric

GlaxoSmithKline and Verily Life Sciences form Galvani Bioelectronics.

Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.

Five people have been indicted for stealing trade secrets from GlaxoSmithKline, the Wall Street Journal reports.

Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.

The institute will develop new technologies and approaches to decode how genes are controlled and how a cell's "operating system" functions. 

Pages

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.